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Abstract 
Background: Aortic root dilatation and—dissection and mitral valve prolapse are established cardiovascular mani‑
festations in Marfan syndrome (MFS). Heart failure and arrhythmic sudden cardiac death have emerged as additional 
causes of morbidity and mortality.
Methods: To characterize myocardial dysfunction and arrhythmia in MFS we conducted a prospective longitudinal 
case–control study including 86 patients with MFS (55.8% women, mean age 36.3 yr—range 13–70 yr–) and 40 age—
and sex‑matched healthy controls. Cardiac ultrasound, resting and ambulatory ECG (AECG) and NT‑proBNP meas‑
urements were performed in all subjects at baseline. Additionally, patients with MFS underwent 2 extra evaluations 
during 30 ± 7 months follow‑up. To study primary versus secondary myocardial involvement, patients with MFS were 
divided in 2 groups: without previous surgery and normal/mild valvular function (MFS‑1; N = 55) and with previous 
surgery or valvular dysfunction (MFS‑2; N = 31).
Results: Compared to controls, patients in MFS‑1 showed mild myocardial disease reflected in a larger left ventricular 
end‑diastolic diameter (LVEDD), lower TAPSE and higher amount of (supra) ventricular extrasystoles [(S)VES]. Patients 
in MFS‑2 were more severely affected. Seven patients (five in MFS‑2) presented decreased LV ejection fraction. Twenty 
patients (twelve in MFS‑2) had non‑sustained ventricular tachycardia (NSVT) in at least one AECG. Larger LVEDD and 
higher amount of VES were independently associated with NSVT.
Conclusion: Our study shows mild but significant myocardial involvement in patients with MFS. Patients with previ‑
ous surgery or valvular dysfunction are more severely affected. Evaluation of myocardial function with echocardiogra‑
phy and AECG should be considered in all patients with MFS, especially in those with valvular disease and a history of 
cardiac surgery.
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Introduction
Marfan syndrome (MFS) (OMIM #154700, ORPHA 
#284963) is an inherited connective tissue disorder 
caused by pathogenic variants in the fibrillin-1 gene 
(FBN1), encoding for the extracellular matrix protein, 
fibrillin-1 [1]. Although aortic root dilatation and—dis-
section and mitral valve prolapse (MVP) are the most 
common and best studied cardiovascular manifestations 
in MFS, heart failure and sudden cardiac death, presuma-
bly secondary to ventricular arrhythmia, seem to be addi-
tional causes of morbidity and mortality to consider in at 
least some of these patients [2, 3].
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Ventricular myocardial dysfunction in MFS is usually 
mild and affects 7–68% of the patients, depending on 
the studied cohort, the technique used and the defini-
tion of ventricular dysfunction [4–10]. End-stage heart 
failure is less common and occurs only in a minority 
of patients [3, 11, 12]. Left ventricular enlargement 
and myocardial dysfunction in MFS can result from 
valvular disease, but primary biventricular myocar-
dial involvement in patients with MFS without valvu-
lar pathology has been shown by several independent 
groups [5–10]. Furthermore, mild myocardial impair-
ment and abnormal myocardial signaling have been 
shown in 2 different murine models of MFS (fbn1mgR/
mgR and fbn1 C1039G/+) [13, 14]. Using one of these 
models (fbn1 C1039G/+), Rouff et al. [15] further showed 
that hemodynamic overload by TAC ligation (trans-
verse aortic constriction), was less well tolerated in 
MFS mice than in wild-type littermates. This finding 
supports the idea that secondary hemodynamic over-
load in a myocardium primarily predisposed to disease 
might cause more damage.
Next to ventricular enlargement or dysfunction, 
myocardial disease might manifest as ventricular 
arrhythmia. The prevalence of sustained ventricular 
tachycardia (VT) and sudden cardiac death (SCD) in 
MFS is approximately 10% and 4% respectively [2, 4, 
16]. An enlarged left ventricle [4, 16, 17] and high lev-
els of NT-proBNP [2, 16] seem to be the most consist-
ent features related to ventricular arrhythmia. Isolated 
MVP without regurgitation, although associated with 
ventricular arrhythmia and SCD in non-MFS popula-
tions [18], has not shown a consistent relation with 
arrhythmia in MFS [2, 4, 16, 17].
Genotype–phenotype correlations have been stud-
ied by a few groups. Aalberts et al. [19] found a higher 
prevalence of left ventricular dilatation in non-mis-
sense FBN1 variant carriers and Aydin et al. [16] found 
that patients carrying a FBN1 missense variant were 
more likely to present ventricular ectopy. Given the 
known relation between left ventricular dimension and 
the presence of ventricular ectopy, these results seem 
contradictory and warrant further study.
To investigate myocardial disease in patients with 
MFS, we conducted a prospective longitudinal case–
control study. The aims of the study were: (1) Com-
pare the prevalence of myocardial dysfunction and 
arrythmia between patients with MFS and sex- and 
age-matched healthy controls. (2) Distinguish primary 
versus secondary myocardial involvement. (3) Iden-




Patients with a clinical diagnosis of MFS according to the 
revised Ghent nosology [1] older than 12 yr and in whom 
a (likely) pathogenic FBN1 gene variant was confirmed, 
were asked to participate in the study. Of the 108 patients 
evaluated in our institution between January 2015 and 
June 2016 and fulfilling the inclusion criteria, 86 agreed 
to participate in this longitudinal study. Six patients 
were excluded due to psychosocial problems (N = 5) or 
residency outside Belgium (N = 1), 11 patients declined 
participation, 4 patients were not included because of 
(planned) pregnancy and 1 patient because of a medi-
cal history of heart transplantation. Forty age- and sex-
matched healthy volunteers were also recruited (Fig. 1). 
To participate in the study, controls could not have a 
(family) history of bicuspid aortic valve, thoracic aortic 
disease or cardiomyopathy.
In all control and MFS subjects, personal medical and 
family history, medication use and conventional cardio-
vascular risk factors (self-reported diabetes, hypercho-
lesterolemia and smoking habits) were documented. 
Anthropometric data and blood pressure after 10  min 
resting were assessed. A 12-lead electrocardiogram 
(ECG), a 24-h ambulatory ECG (AECG) and a standard 
cardiac ultrasound were performed. NT-proBNP was 
measured at baseline. Additionally, patients with MFS 
were followed for a mean duration of 30 ± 7  months. 
During follow-up, they underwent annual ECG and 
24 h AECG recording, cardiac ultrasound and measure-
ment of NT-proBNP. Since thyroid function is associated 
with higher risk of arrythmia [20, 21], levels of TSH were 
measured in all patients at the end of the study to rule out 
(sub)clinical thyroid disease.
To evaluate primary versus secondary myocardial dis-
ease, patients with MFS were divided in two groups: the 
1st group without medical history of cardiovascular sur-
gery [aortic root replacement (AoRR) or isolated mitral 
valve surgery] and without moderate to severe mitral or 
aortic regurgitation. This group is further referred in the 
text as MFS-1 (N = 55). The 2nd group of patients with 
either cardiovascular surgery or with valvular disease (or 
both), is further referred in the text as MFS-2 (N = 31).
Study procedures
Cardiac ultrasound was performed with a Vivid  S60N®, 
GE Healthcare, equipped with a 5S probe. Aortic diam-
eters, valvular function as well as cardiac chamber 
dimensions and—function were measured according 
to the guidelines of the American Society of Echo-
cardiography (ASE) and the European Association of 
Cardiovascular Imaging (EACVI) [22, 23]. Data were 
Page 3 of 11Muiño‑Mosquera et al. Orphanet J Rare Dis          (2020) 15:300  
stored and analyzed offline using an ultrasound work-
station (EchoPAC, GE Healthcare, version 201). For 
the continuous variables, an average of 3 consecu-
tive measurements was calculated. Aortic and mitral 
valve regurgitation were graded into mild, moderate 
or severe and mitral valve prolapse was considered 
if there was a superior mitral leaflet displacement of 
more than 2 mm in systole. Z-scores of the aortic sinus 
and proximal ascending aorta were calculated accord-
ing to Campens et  al. [24]. For evaluation of diastolic 
function, a combination of pulsed wave and tissue dop-
pler imaging (TDI) was used. LV ejection fraction (EF) 
was calculated from a 2D image in parasternal long-
axis view (LVEF = LVEDD2-LVESD2/LVEDD2*100 + k, 
where LVEDD = left ventricular end diastolic diameter, 
LVESD = left ventricular end systolic diameter, k = cor-
rection for apical contraction). Systolic dysfunction was 
defined as LVEF < 55% [23]. Mid-wall fractional short-
ening (mw-FS), left ventricular mass (LVM) and relative 
wall thickness (RWT) were also derived from the 2D 
image in parasternal long-axis using the formulas rec-
ommended by the ASE and EACVI [23]. A LVEDD was 
considered enlarged if indexed for body surface area 
(BSA)(LVEDDi) was above 30 mm/m2 [23]. The tricus-
pid annular plane systolic excursion (TAPSE) viewed 
from the four-chamber view was used to evaluate right 
ventricular function. TAPSE was considered abnormal 
if ≤ 16 mm.
A routine 12-lead ECG was recorded using an avail-
able commercial system (MAC 5500 HD, GE Health-
care). Regular measurements of P-wave width and 
height, P-wave axis, PR-interval, QRS width and axis, 
and QTc interval using Bazett’s formula were calcu-
lated. The U-wave was included in the measurement of 
the QTc interval if > 50% of the T-wave height. A stand-
ard AECG was performed and analyzed using 2 semi-
automatic software packages (Philips DigiTrack  XT®, 
Philips and Trillium Platinum  TM®, Forest Medical). 
Minimum, maximum and average heart rate, number of 
supraventricular—(SVES) and ventricular extrasystoles 
(VES) were recorded. Atrial runs and non-sustained 
ventricular tachycardia (NSVT) were defined as 3 or 
more consecutive atrial or ventricular beats. Sustained 
ventricular tachycardia (VT) was defined if VT lasted 
30  s or more. Ventricular ectopy (VE) was defined if 
more than 10 VES/h. Heart rate variability (HRV) was 
studied using the standard deviation of the normal-
to-normal interval (SDNN) and the square root of the 
mean squared difference of successive normal-to-nor-
mal intervals (RMSDD).
Fig. 1 Inclusion procedure and investigations at baseline and during follow‑up. Eighty‑six patients with MFS and 40 age‑ and sex matched controls 
were included in the study. At baseline all subjects underwent physical examination, resting and ambulatory ECG, cardiac ultrasound and dosing 
of NT‑proBNP. In patients with MFS these investigations were repeated twice, in a mean period of 30 ± 7 months and TSH level was determined at 
the end of the study. Additionally, a subset of 45 patients underwent cardiac MRI with angiography and measurement of PWV. Eighty‑two patients 
completed all 3 visits. Three patients died during study, 2 of them after completing the 3rd visit. Two patients declined further participation after the 
1st visit and 1 patient could not attend the last visit. AECG ambulatory ECG, ECG electrocardiogram, MFS Marfan syndrome, MRI magnetic resonance 
image
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Classification of the genetic variants
To study genotype–phenotype correlations, variants in 
the FBN1 gene were classified according to their effect 
on the DNA structure as missense (single nucleotide 
change), in-frame (indels not causing alteration in the 
reading frame), frameshift (indels causing an altera-
tion in the reading frame), nonsense (single nucleotide 
change causing a premature stop-codon) and splice-site 
variants (indels or single nucleotide change in a place 
where splicing occurs).
Variants were also classified according to the 
expected effect at the protein level [25]. Frameshift and 
nonsense variants not affecting exon 65 or the last 50 
nucleotides of exon 64 were considered to have an hap-
loinsufficient (HI) effect, leading to the production of 
a reduced amount of normal fibrillin-1 (derived from 
the non-mutated allele). The other frameshift and non-
sense variants and all missense variants were consid-
ered to have a dominant negative (DN) effect, leading 
to a shorter or a structurally abnormal but stable pro-
tein. These predictions were confirmed by the Muta-
tion Taster software [26]. To classify the effect of the 
splice-site variants we used the Human Splicing Finder 
Software [27]. Splice-site variants causing a change in 
the reading frame were considered as HI, while variants 
affecting splicing but not causing a change in the read-
ing frame were considered as DN.
Furthermore, we considered variants affecting exon 
24–32 separately because these have been previously 
associated with higher ventricular ectopy [16].
Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics 25 package (SPSS Inc., Chicago, IL, USA).
Continuous variables are expressed as mean and stand-
ard deviation or as median and interquartile range (IQR). 
Categoric variables are expressed as absolute value and 
percentage.
The Kolmogorov–Smirnov test was used to determine 
normality. Continuous variables were analyzed either 
using the unpaired sample t-test and the Mann–Whit-
ney-U if two groups were compared or the ANOVA and 
Kruskal–Wallis if more than 2 groups were compared. 
For the categorical variables Chi-square test or the Fisher 
exact test were used. Variables were adjusted for con-
founders using either linear regression for continuous 
variables or logistic regression for categoric variables. 
Those variables with a p-value < 0.2 were considered as 
possible confounders. Since NT-ProBNP and the amount 
of ventricular extrasystoles (VES) in 24 h were extremely 
skewed, a logarithmic transformation was performed to 
include them in the multivariable analysis.
Ethical issues
The study was approved by the local Independent Ethics 
Committee and the Institutional Review Board (IRB) of 
our hospital. All subjects participating in the study gave 
written informed consent.
Results
Baseline characteristics and comparison between Marfan 
syndrome patients and control subjects
Eighty-six patients with MFS (55.8% female, 
36.3 ± 14.3  yr—range 13–70  yr–) and 40 age- and sex-
matched controls (52.5% female, 37.9 ± 14.4  yr—range 
16–69  yr) were included in the study. One of the study 
patients declined AECG (Fig. 1).
Twenty-four patients had undergone cardiovascu-
lar surgery at baseline (21 AoRR, 2 mitral valve surgery 
alone and 1 patient both). Eleven patients had moderate 
to severe valvular disease (5 mitral valve regurgitation, 
4 aortic valve regurgitation and 1 both) of whom 7 had 
not undergone cardiovascular surgery. These 31 patients 
formed the MFS-2 group. Eight patients had previously 
been treated or were currently under treatment for atrial 
arrhythmia (4 atrial fibrillation and 4 with another type 
of supraventricular tachycardia) and 3 patients had been 
treated for symptomatic ventricular ectopia (2 medical 
treatment and 1 ablation). As shown in Table 1 patients 
in the MFS-1 and MFS-2 groups did not differ signifi-
cantly except for in the incidence of atrial events in their 
medical history. Afib in particular was more frequent 
in the MFS-2 group. In the control group, except for 
one woman of 69  years old who had undergone coiling 
for a cerebral aneurysm, no one had a significant medi-
cal history. Two controls had smoked in the past, 2 were 
treated for arterial hypertension and 7 reported to have 
hyperlipidemia.
As shown in Table 2, while 7 (8.1%) of the patients with 
MFS had mildly decreased LVEF (5 in the MFS-2 group), 
decreased LVEF was no present in control subjects.
Demographic characteristics in the group with 
decreased LVEF were similar to the rest of the MFS 
cohort (Additional file  1: Table  S1). Median LVEF in 
this group was 53.1% (IQR 47.1–53.7%). As expected, 
LVEDDi and LVESDi were significantly higher in 
patients with decreased LVEF (28.2 ± 3.5  mm/m2 ver-
sus 25.3 ± 3.5  mm/m2, p = 0.038 and 21.7 ± 2.6  mm/m2 
versus 16.6 ± 2.7  mm/m2, p < 0.001, respectively). Nine 
patients (10.5%) had a TAPSE value ≤ 16  mm (6 in the 
MFS-2 group).
To assess whether myocardial involvement in MFS has 
a primary component, we compared control subjects 
with those MFS-1 patients without previous surgery or 
valvular disease. As shown in Table  2, mild biventricu-
lar myocardial involvement in MFS-1 was evidenced by 
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significantly higher NT-proBNP, left ventricular dimen-
sion, E/Em ratio and lower RWT and TAPSE. Further-
more, MFS-1 patients showed longer QRS-duration and 
QTc time at rest ECG. NSVT only occurred in patients 
with MFS. SDNN and RMSDD were significantly higher 
in MFS-1 even after adjusting for beta-blocker use 
(p = 0.008 and p = 0.027, respectively).
In comparison to MFS-1 patients, MFS-2 patients 
showed significantly larger left ventricular dimensions, 
lower left ventricular ejection fraction, mw-FS and 
TAPSE, higher NT-proBNP and longer QTc time. QTc 
time was abnormal (> 460 ms) in 4 patients in the MFS-2 
group. Systolic blood pressure was also slightly but sig-
nificantly higher in MFS-2 patients (Table 2). SDNN and 
RMSDD were significantly lower in MFS-2 and similar to 
the control population.
Events during follow‑up and AECG characteristics 
in subsequent examinations
All patients except 4 completed the study (one patient 
died and 2 patients declined further participation 
after visit 1 and one patient could not attend the last 
visit—Fig. 1).
During a follow-up period of 30 ± 7 months 3 patients 
died from (suspected) aortic dissection or rupture (2 type 
A and 1 type B). Two of them died just after completing 
the 3rd visit (Fig. 1). Four other patients survived a dis-
section (1 coronary dissection, 1 type B dissection and 2 
type A dissections). Prophylactic AoRR was performed 
in 6 patients and aortic valve replacement with mechani-
cal prosthesis in an additional patient who had previous 
AoRR.
As shown in Additional file  1: Table  S2, LVEDD and 
LVEF remained stable during the study follow-up. There 
were no patients showing heart failure symptoms dur-
ing follow-up. The overall amount of VES on 24 h AECG 
in patients with MFS at baseline was low (7.5 VES/24 h 
IQR 1–98). However, 20 patients (23.3%) showed NSVT 
on one or more of the 24  h AECG (10 at the 1st exam, 
10 additionally during the 2 consecutive exams). 80% of 
these patients was under treatment with a beta-blocker 
(Table  3). Only one patient in this group, showed sus-
tained VT during follow-up. He was 30 years old at the 
time of the first sustained VT episode and had had AoRR 
and MV surgery 4 months earlier. An ICD was implanted 
and showed recurrent episodes of VT under beta-
blocker therapy. VT was only controlled with amiodar-
one therapy. No patients in the study developed SCD or 
arrhythmogenic syncope during the study period.
To identify factors associated with NSVT we com-
pared the 20 patients having NSVT with the rest of the 
MFS cohort. Univariate analysis showed that LVEDDi, 
LVESDi, NT-proBNP and the amount of VES/24 h were 
Table 1 Baseline characteristics of  the  patients 
with Marfan syndrome
ACEi angiotensin converting enzyme inhibitor, Afib atrial fibrillation, AoRR 
aortic root replacement, ARB angiotensin II receptor blocker antagonist, BB 
beta‑blocker, BMI body mass index, EL ectopia lentis, HTA arterial hypertension, 
MV mitral valve, MVP mitral valve prolapse, SVT supraventricular tachycardia, VE 
ventricular ectopy
a Marfan systemic score is a scoring system which takes into consideration 
several characteristic features of MFS and assigns each of them a value between 
1 and 3, 3 being the most specific for the disease. A score of ≥ 7 is considered 
abnormal and in combination with aortic disease and/or ectopia lentis is 
diagnostic of MFS
b Patients reporting palpitations in the past were not included. Only confirmed 
atrial and ventricular ectopy for which treatment was implemented were 
considered
Parameter MFS‑1 (N = 55) MFS_2 (N = 31) p value
Female (%) 31 (56.4) 17 (54.8) 0.891
Age 35.07 ± 14.7 38.5 ± 13.7 0.295
FBN1 variant type (%) 0.296
 Missense 29 (53.7) 13 (41.9)
 Frameshift 13 (24.1) 7 (35)
 Nonsense 9 (16.7) 6 (19.4)
 Splice‑site 2 (28.6) 5 (71.4)
 De novo (%) 17 (30.9) 8 (26.7) 0.682
Systemic  scorea 8.02 ± 3.3 8.7 ± 3 0.401
EL (%) 25 (48.1) 21 (70) 0.149
AoRR (%) 0 22 (71) n.a
 Valve sparing (%) 16 (72.7)
 Valve replacement (%) 6 (27.3)
MVP (%) 0.393
 Bulging 17 (52.8) 7 (23.3)
 Prolapse 8 (15.1) 8 (26.7)
MV surgery (%) 0 3 (9.3) n.a
 Valvuloplasty and ring (%) 1
 Bioprosthesis (%) 1
 Mechanical valve (%) 1
Atrial arrhythmia (%)b 0.016*
 Afib (%) 0 4 (12.9)
 Other SVT (%) 2 (3.6) 2 5 (6.4)
Symp. VE (%)b 1 2 0.261
Treatment 0.206
 None (%) 16 (29.1) 3 (9.7)
 BB alone (%) 19 (34.5) 16 (51.6)
 ARB alone (%) 6 (10.9) 3 (9.7)
 ACEi alone (%) 1 (1.8) 0
 BB + ARB (%) 13 (23.6) 8 (25.8)
 BB + ACEi (%) 0 1 (3.2)
BMI ≥ 25 kg/m2 (%) 13 (23.6) 7 (23.3) 0.365
Smoking (%) 0.979
 Never 38 (69.1) 22 (71)
 Ex‑smoker 11 (20) 6 (19.4)
 Current 6 (10.9) 3 (9.7)
AHT (%) 6 (10.9) 2 (6.5) 0.494
Hyperlipidaemia (%) 5 (9.1) 3 (9.7) 0.844
Diabetes (%) 3 (5.5) 0 0.186
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Table 2 Comparison between  control subjects and  patients with  Marfan syndrome with  and  without valvular disease 
and/or cardiovascular surgery
Values are given as mean ± SD, median (IQR) or number (%)
Ao aortic, BB beta‑blocker, BSA body surface area, DBP diastolic blood pressure, Dec time deceleration time, HR heart rate, LAVi left atrium volume index, LVEDDi 
left ventricular end diastolic diameter index, LVEF left ventricular ejection fraction, MFS Marfan syndrome, MVP mitral valve prolapse, mw-FS mid‑wall fractional 
shortening, NSVT non‑sustained ventricular, RMSDD mean squared difference of successive NN intervals, RWT relative wall thickness, SBP systolic blood pressure, SDNN 
standard deviation of the NN interval, SVES supraventricular extrasystoles, VES ventricular extrasystoles, TAPSE tricuspid annular plane systolic excursion, VE ventricular 
ectopy
a Beta‑blocker alone or in combination
b Only those patients with valvular pathology without aortic root replacement are considered for the mean value of the sinus and the z‑score
c Only those patients with true mitral valve prolapse considered here. Those with mitral valve bulging were not included in this calculation
Control subjects Patients with Marfan syndrome p value p value




No valvular disease Valvular disease
N = 55 (MFS‑1) N = 31 (MFS‑2)
Female (%) 22 (55) 31 (56.4) 17 (54.8) 0.895 0.891
Age (%) 37.9 ± 14.4 35.1 ± 14.7 38.5 ± 13.7 0.370 0.295
Height (cm) 173 ± 10 183.2 ± 11 183.9 ± 9.5  < 0.001 0.771
Weight (kg) 68.3 ± 9.2 74.2 ± 17.9 74.1 ± 18.3 0.041 0.987
BSA  (m2) 1.8 ± 0.1 1.9 ± 0.2 1.9 ± 0.2 0.001 0.923
SBP (mmHg) 121.1 ± 12.7 121 ± 12.6 127.3 ± 15.9 0.899 0.049
DBP (mmHg) 73.7 ± 9.6 71.6 ± 70 67 ± 10.1 0.361 0.067
BB Use (%)a 0 (0) 32 (58.2) 25 (80.6) n.a 0.034
Ao sinus (mm) 30.5 ± 2.9 39.8 ± 5.1 41.1 ± 6.6b  < 0.001 0.498
z‑score sinus  − 0.8 ± 0.7 2.5 ± 1.4 3.3 ± 1.1b  < 0.001 0.094
LVEDDi (mm/m2) 24.7 ± 2.4 24.8 ± 3.4 26.7 ± 3.5 0.795 0.020
LVEDDi ≥ 30 mm/m2 (%) 0 (0) 5 (9.1) 4 (12.9) 0.050 0.717
iLVM 86.9 ± 20.2 81 ± 34.7 86.2 ± 23.04 0.331 0.486
LVEF (%) 68.3 ± 7.2 66 ± 7.2 62.5 ± 7.6 0.131 0.034
LVEF < 55% 0 (0) 2 (3.6) 5 (16.1) 0.507 0.093
mw‑FS (%) 21 ± 7 21 ± 5 16 ± 6 0.778 0.004
RWT 0.45 (0.40–0.50) 0.37 (0.32–0.45) 0.33 (0.29–0.40)  < 0.001 0.060
E/A 1.5 (1.2–2) 1.6 (1.3–2) 1.6 (1.2–2.1) 0.351 0.975
E/E’ 6.4 (5.1–7.6) 7.8 (6.6–9.3) 8.6 (7–12.8)  < 0.001 0.051
LAVi (ml/m2) 21.2 ± 5.5 21.4 ± 1.3 26.4 ± 11.3 0.945 0.038
MVP (%)c 1 (2.5) 8 (14.5) 8 (26.7) 0.045 0.185
TAPSE (mm) 24.5 ± 2.8 22.1 ± 4.3 19.5 ± 3.8 0.003 0.010
TAPSE ≤ 16 mm (%) 0 (0) 3 (6.4) 6 (20.7) 0.250 0.077
NT‑ProBNP (pg/ml) 30 (19–44.5) 53.5 (30–74.2) 129 (82–235.2) 0.001  < 0.001
Min HR (bpm) 50.5 (44–55.5) 45 (41.5–49) 48 (44–55) 0.004 0.026
Average HR (bpm) 74.2 ± 8.3 64 (56.5–71.5) 67 (58.5–73)  < 0.001 0.205
QRS width (ms) 80 (80–90) 96 (86–104) 98 (86–106)  < 0.001 0.639
QTc (ms) 380.2 ± 24.5 414 (388–433.5) 426 (407–445)  < 0.001 0.028
QTc > 460 ms (%) 0 (0) 0 (0) 4 (12.9) n.a n.a
SVES/24 h 2 (0.25–4.7) 7 (2–37.5) 17 (1–56)  < 0.001 0.560
Atrial runs (%) 2 (5) 14 (26.4) 12 (41.4) 0.015 0.318
VES/24 h 0 (0–5.7) 6 (1–69.5) 14 (1.5–373.5)  < 0.001 0.312
VE (%) 5 (12.5) 14 (26.4) 13 (41.9) 0.099 0.090
Vent couplets (%) 2 (5) 9 (17) 8 (25.8) 0.077 0.270
NSVT (%) 0 (0) 5 (9.1) 5 (17.2) 0.050 0.273
SDNN (ms) 147 (116–185.2) 185 (156.2–219.2) 132 (95.4–191) 0.001 0.003
RMSDD (ms) 53 (36.2–84) 82.5 (66.2–82.5) 59.3 (42.7–112)  < 0.001 0.040
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significantly higher in the group with NSVT (Table  3). 
Furthermore, NSVT during follow-up occurred more 
frequently in the MFS-2 group than in the MFS-1 group 
(40% versus 14.5%, p = 0.008). In multivariate analysis, 
however, only LVEDDi and VES/24 h were independently 
associated with NSVT (Fig.  2). These 2 variables were 
associated with NSVT independently from each other.
Other factors such as the presence of MVP or increased 
E/Em ratio tended to be higher in the group with NSVT 
but was not statistically significant. We could not identify 
variables on the resting ECG or parameters of HRV asso-
ciated with the presence of NSVT.
At baseline patients in the MFS-2 group had signifi-
cantly higher amounts of atrial events (SVT or Afib) in 
their medical history compared to patients in the MFS-1 
group. Although baseline AECG showed higher amounts 
of supraventricular extrasystoles and atrial runs in the 
MFS-1 group compared to controls, the prevalence of 
these events was similar between both MFS groups, as 
shown in Table 1. During follow-up 4 patients presented 
Afib, 2 in the MFS-1 group and 2 in the MFS-2 group. 
A description of clinical characteristics of these patients 
can be found in the Additional file 1: Table S3’.
Seven patients were under treatment for thyroid dis-
ease during the study period (6 women for hypothyroid-
ism with levothyroxine and 1 male for hyperthyroidism 
with thiamazole). Within the patients with hypothyroid-
ism, one had NSVT during FU and one a history of Afib. 
All other patients, except for 1 with slightly elevated TSH 
(5.4  mU/l), had normal values (reference value in our 
institution 0.4–4 mU/l). This patient showed no arrhyth-
mic events on his three AECGs.
Genotype–phenotype correlations
As shown in Table 4, the presence of NSVT was not asso-
ciated with a specific type of FBN1 variant. We observed, 
however, that those patients carrying a missense variant 
tended to have less arrhythmia. Four out of the 7 patients 
(57.1%) with decreased LVEF carried a frameshift variant. 
This was significantly higher than in the group with nor-
mal LVEF (20.5%, p = 0.050). No other genotype–pheno-
type correlations were found.
Discussion
In our study, we show mild myocardial involvement in 
patients with MFS, even in those without valvular disease 
or previous cardiovascular surgery. Prevalence of NSVT 
was rather high in MFS, presenting in almost a quarter of 
the patients either at baseline or during follow-up. Those 
patients with valvular and/or cardiovascular surgery in 
the past seemed to have higher risk of myocardial dis-
ease. Atrial events were higher in MFS patients than in 
Table 3 Comparison between  patients with  and  without 
non-sustained ventricular tachycardia
Values are given as mean ± SD, median (IQR) or number (%)
Ao aortic, AoRR aortic root replacement, AR aortic regurgitation, BB beta‑blocker, 
BSA body surface area, DBP diastolic blood pressure, ECG electrocardiogram, HR 
heart rate, LAVi left atrium volume index, LVEDDi left ventricular end diastolic 
diameter index, LVESDi left ventricular end systolic diameter index, LVEF left 
ventricular ejection fraction, LVMi left ventricular mass index, MFS marfan 
syndrome, MR mitral regurgitation, MV mitral valve, MVP mitral valve prolapse, 
mw-FS mid‑wall fractional shortening, NSVT non‑sustained ventricular, RAVi 
right atrium volume index, RMSDD mean squared difference of successive NN 
intervals, RVOT right ventricular outflow track, RWT relative wall thickness, 
SBP systolic blood pressure, SDNN standard deviation of the NN interval, SVES 
supraventricular extrasystoles, TAPSE tricuspid, annular, plane systolic excursion, 
VES ventricular extrasystoles
a MFS systemic score is a scoring system which takes into consideration several 
characteristic features of MFS and assigns each of them a value between 1 and 3, 
3 being the most specific for the disease. A score of ≥ 7 is considered abnormal 
and in combination with aortic disease and/or ectopia lentis is diagnostic of MFS
b One patient declined 24 h AECG
Non‑sustained ventricular tachycardia
Present (n = 20) Absent (n = 65b) p value
Female (%) 10 (50) 37 (59.7) 0.604
Age (yrs) 40.3 ± 15.7 35.2 ± 13.8 0.170
BSA (kg/m2) 21.3 (19–25.5) 21.4 (18.6–24.8) 0.821
SBP (mmHg) 124.3 ± 12.8 122.1 ± 14.5 0.549
DBP (mmHg) 67.7 ± 5.7 70.1 ± 10.9 0.365
BB use (%) 16 (80) 39 (62.9) 0.157
MFS systemic  scorea 8 (4–11) 8 (6–10) 0.657
MFS group 0.008
 MFS‑1 (N = 55) (%) 8 (40) 47 (72.3)
 MFS‑2 (N = 30b) (%) 12 (60) 18 (27.7)
Cardiac ultrasound
 Ao sinus (mm) 39.9 ± 4.3 40.1 ± 5.6 0.906
 MVP (%) 7 (35) 9 (15.3) 0.058
 LVEDDi (mm/m2) 27.9 ± 3.6 24.8 ± 3.2  < 0.001
 LVESDi (mm/m2) 18.4 ± 3 16.7 ± 2.7 0.028
 LVEF (%) 63.6 ± 8.2 65.2 ± 7.4 0.419
 Mw‑FS (%) 21 ± 9 19 ± 6 0.344
 RWT 0.36 (0.31–0.44) 0.35 (0.29–0.40) 0.354
 RVOTi (mm/m2) 15.9 ± 2.4 15.4 ± 2.7 0.476
 TAPSE (mm) 20.8 ± 3.7 21.7 ± 4.2 0.448
 LAVi (mm/m2) 24.2 (14–29.2) 21.2 (15.2–28.6) 0.854
 E/A ratio 1.6 ± 0.6 1.7 ± 0.6 0.723
 E/Em ratio 9.5 (7.1–11.7) 7.8 (6.6–9.7) 0.100
Serologic test
 NT‑ProBNP (pg/ml) 112 (78.5–216.5) 60 (31–129) 0.017
Ambulatory ECG
 Min HR (bpm) 47 (42–51) 46 (42.2–50) 0.792
 Average HR (bpm) 67 (58–72) 65.5 (57.2–72.7) 0.991
 Max HR (bpm) 122 (100–133) 120.5 (101–142) 0.684
 QRS width (ms) 100 (90.5–109.5) 96 (82.5–101.5) 0.075
 Qtc time (ms) 426 (403–443.2) 413 (385.2–432) 0.199
 VES/24 h 345 (9–3727) 4 (1–35) 0.001
 SDNN (ms) 177 (126.1–264.6) 176 (140–203.5) 0.620
 RMSDD (ms) 74 (58–159.9) 79.5 (57.9–109) 0.790
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controls and Afib occurred in 9% of the patients in our 
cohort.
Mild but significant myocardial dysfunction in patients 
with MFS has been reported earlier in several independ-
ent studies [4–10]. Although we did not study the role of 
aortic stiffening in myocardial involvement, the fact that 
we noticed mild myocardial dysfunction and a higher rate 
of arrhythmic events in MFS-1 patients suggests primary 
myocardial involvement. Furthermore, the fact that the 
majority of the patients with reduced ejection fraction 
were carrying a truncating variant and that we found a 
similar trend for those patients with NSVT, suggests that 
Fig. 2 Multivariate analysis to identify independent associations with NSVT in patients with Marfan syndrome. Multivariate analysis shows that 
higher left ventricular dimension and higher amount of VES in the AECG are the only independent factors of the presence of NSVT. ln logarithm, 
LVEDDind left ventricular end diastolic diameter index, MFS Marfan syndrome, ln logarithm, yr year, VES ventricular extrasystoles
Table 4 Comparison of  the  genotype between  patients with  and  without arrhythmia and  with  normal or  decreased 
ejection fraction
Values are given as number (%)
a Variant details were lacking in one patient. Another patient declined ambulatory ECG
Non‑sustained ventricular tachycardia Left‑ventricular ejection fraction
Present (n = 20) Absent (n = 64)a p value  < 55% (n = 7)  ≥ 55% (n = 77) p value
Type of variant
 Missense (%) 7 (35) 35 (54.7) 0.100 1 (14.3) 41 (52.6) 0.058
 Inframe (%) 1 (5) 0 (0) 0.238 0 (0) 1 (10.3) 0.918
 Frameshift (%) 5 (25) 14 (21.9) 0.494 4 (57.1) 16 (20.5) 0.050
 Nonsense (%) 4 (20) 11 (17.2) 0.747 0 (0) 15 (19.2) 0.243
 Splice‑site (%) 3 (15) 4 (6.3) 0.349 2 (28.6) 5 (6.4) 0.100
Effect on the protein
 Haploinsufficiency (%) 9 (45) 24 (37.5) 0.128 4 (57.1) 30 (38.5) 0.283
Localization: exon
 Exon 24–32 (%) 2 (10) 8 (12.5) 0.559 0 (0) 10 (12.8) 0.402
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there is a genetic predisposition, independent of hemo-
dynamic overload, to develop myocardial disease. These 
findings are in line with the findings of Aalberts et  al. 
[19] and with the general observation that variants caus-
ing a HI effect (like most of the truncating variants) are 
associated with a more severe cardiovascular phenotype 
[28–31]. On the other hand we demonstrate that those 
patients with valvular disease and past history of cardi-
ovascular surgery, have larger left ventricular diameters 
and lower ejection fraction, indicating that hemodynamic 
overload (as expected) also plays an important role in the 
pathophysiology of MFS cardiomyopathy. Patients with 
NSVT in consecutive AECGs did not show progression 
of valvular dysfunction but we did observe that more 
patients in the MFS-2 group showed more NSVT during 
follow-up. We think that this is more related to the prior 
aortic surgery than to progression of valvular disease. We 
did not include a specific control group for MFS-2 (non-
Marfan syndrome patients after cardiovascular surgery 
or valvular disease), therefore we are not able to assess 
whether the effect of hemodynamic overload is more sig-
nificant in MFS in comparison to the general population.
So far, 6 studies, ours included, have investigated ven-
tricular arrhythmia in MFS in detail [2, 4, 16, 17, 32]. 
Additional values of our study are the inclusion of a con-
trol population and the availability of serial 24 h AECGs 
in patients with MFS. Although in control subjects iso-
lated ventricular extrasystoles are a relatively common 
finding, present in 12.5% of the subjects, NSVT was only 
present in patients with MFS. Two questions which we 
have not been able to resolve however, are: (1) does the 
presence of NSVT predispose to life threatening arrhyth-
mias? And (2) is it necessary to treat NSVT to prevent 
adverse events? The prognostic value of NSVT in non-
MFS patients is very variable [33] and the available evi-
dence to answer this question for patients with MFS 
is very limited. Yetman et  al. [4] found that ventricular 
ectopy (defined as > 10  VES/h, the presence of couplets 
or NSVT) was an independent risk factors of SCD. In 
contrast, although Hoffman et al. [2] and Aydin et al. [16] 
found a higher amount of NSVT in those patients with 
ventricular arrhythmic events, these differences were 
not significant after multivariate analysis. In our study, 
no patient presented SCD or arrhythmogenic syncope 
and therefore we were not able to assess the predictive 
value of NSVT. Nevertheless, the high prevalence of 
NSVT in our study contrasts with the low prevalence of 
SCD, suggesting that NSVT might not be the best pre-
dictor of SCD. In our cohort, the only patient develop-
ing sustained VT, showed progressive ventricular ectopy 
over the years. After implantation of an ICD, sustained 
VT kept occurring under beta-blocker treatment. Based 
on our experience and the fact that in the publication 
of Yetman et al. [4], 2 of the 3 cases of SCD were under 
treatment with beta-blocker, we think that treatment of 
ventricular ectopy with beta-blockers alone seems insuf-
ficient, but further study in a larger cohort is warranted.
Another matter of debate is the underlying mechanism 
responsible for the ventricular ectopy. So far an enlarged 
LV diameter seems to be the most consistent independ-
ent factor associated with an arrhythmic event [4, 16, 17]. 
Although in the publication of Hoffman et al. LV diam-
eter was not independently associated with SCD and 
sustained VT, NT-proBNP, a marker of myocardial dis-
ease, showed to be a good predictor of these events. NT-
proBNP, in our cohort, was also higher in those patients 
with NSVT, but we could not find a very strong associa-
tion. The levels of NT-proBNP in our patients with MFS 
were overall within normal values (68.50  pg/ml, IQR 
35.3–149.3) which might explain the lack of association.
A peculiar finding was that the 2 parameters of heart 
rate variability (SDNN and RMSDD) were increased in 
patients with MFS without valvular disease or surgery 
independently of beta-blocker use. Heart rate variability 
refers to the fluctuation in the beat-to-beat interval of a 
patient’s heart rate and reflects the autonomic activity 
of the heart. Lower values of heart rate variability have 
been related to left ventricular dysfunction and a higher 
incidence of arrhythmia after myocardial infarction in 
the general population [34]. In patients with MFS, how-
ever, its use has been very limited and actually, higher 
values of heart rate variability have been associated 
with cardiovascular risk. Hoffman et  al. [2] showed sig-
nificantly higher RMSSD in those patients reaching the 
composite end point (ventricular tachycardia or fibrilla-
tion, arrhythmogenic syncope or sudden cardiac death) 
and Mah et al. [17] showed higher values of the triangu-
lar index (another parameter of heart rate variability) in 
those patients with worse aortic outcome. In our study, 
we could not establish an association between heart rate 
variability and NSVT or reduced left ventricular func-
tion. Further study of autonomic function in patients 
with MFS could be interesting to gain a better under-
standing of its relation to the clinical outcome.
Limitations and future perspectives
One of the most important limitations of our study is the 
sample size and the low number of events. These have 
precluded us from answering some important ques-
tions. Furthermore, we measured left ventricular func-
tion with a solid but low sensitive technique (LVEF and 
md-FS). Using strain analysis might have yielded a better 
result. Next to these limitations, our control group was 
relatively small. Taking a larger control group and per-
forming several AECG might have also detected NSVT 
in healthy individuals.
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The underlying cause of ventricular ectopy should be 
better elucidated. For example, we did not address myo-
cardial fibrosis as underlying mechanism of ventricular 
dysfunction and arrhythmia. A small study with cardiac 
MRI in 35 children with MFS (N = 14) and Loeys-Dietz 
syndrome (N = 21) showed increased markers of myocar-
dial fibrosis in patients compared to an age-matched con-
trol population [35]. Another clue to better understand 
the pathophysiology of arrhythmia, could be determining 
the location of the ventricular ectopy. In our study, solely 
based on the 24 h AECG, it was challenging to accurately 
determine the ectopic foci. Therefore, electrophysiologic 
studies in a selected group of patients might be useful. 
Furthermore, in our study, mitral valve prolapse in itself 
did not seem to be highly correlated with higher inci-
dence of ventricular arrhythmia, however other studies 
did find this correlation. It is possible that not so much 
mitral valve prolapse, but mitral valve annular disjunc-
tion (MAD) might be the underlying cause of arrhyth-
mia in MFS, as it has been shown in non-MFS patients 
with MAD [36]. This correlation should be studied more 
in-depth.
Conclusion
Patients with MFS have mild but significant myocar-
dial dysfunction and a higher frequency of ventricular 
arrhythmia in comparison to healthy subjects. Although 
the overall amount of VES in patients with MFS was low, 
almost a quarter of the patients presented NSVT. Based 
on these facts we recommend surveillance of myocardial 
function and arrhythmia in all patients with MFS. Those 
patients with increased LV diameter, decreased LV func-
tion, palpitations or additional cardiovascular risk factors 
including valvular disease and surgery, form a higher risk 
population.
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